Lobbying client

FIGHTSMA

Filings
44
Filed by
1
Reported in-house
—
Reported by firms
$895,000

Reported lobbying by year

The larger of in-house and firm-reported each year, $ thousands 2007 to 2017

Filings

44 filings, newest first.
Filing Filed by Amount
4th Quarter - Termination
4th Quarter 2017
PUBLIC STRATEGIES WASHINGTON, INC. $20,000 reported
3rd Quarter - Report
3rd Quarter 2017
PUBLIC STRATEGIES WASHINGTON, INC. $20,000 reported
2nd Quarter - Report
2nd Quarter 2017
PUBLIC STRATEGIES WASHINGTON, INC. $20,000 reported
1st Quarter - Report
1st Quarter 2017
PUBLIC STRATEGIES WASHINGTON, INC. $20,000 reported
4th Quarter - Report
4th Quarter 2016
PUBLIC STRATEGIES WASHINGTON, INC. $20,000 reported
3rd Quarter - Report
3rd Quarter 2016
PUBLIC STRATEGIES WASHINGTON, INC. $20,000 reported
2nd Quarter - Report
2nd Quarter 2016
PUBLIC STRATEGIES WASHINGTON, INC. $20,000 reported
1st Quarter - Report
1st Quarter 2016
PUBLIC STRATEGIES WASHINGTON, INC. $20,000 reported
4th Quarter - Report
4th Quarter 2015
PUBLIC STRATEGIES WASHINGTON, INC. $15,000 reported
3rd Quarter - Report
3rd Quarter 2015
PUBLIC STRATEGIES WASHINGTON, INC. $15,000 reported

Filed by

Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.

FirmReportsAmount
PUBLIC STRATEGIES WASHINGTON, INC. 42 $895,000

Issues lobbied

How many report sections named each issue, counting the current version of each report.

IssueCodeMentions
Health Issues HCR 43
Budget/Appropriations BUD 14

Bills named in its filings

Bill numbers found in the filers' descriptions, most often named first.

BillCongressTimes named
S. 424 113th 7
H.R. 225 113th 7
H.R. 2149 111th 7
S. 1158 111th 7
S. 252 113th 4
S. 2042 110th 4
H.R. 3334 110th 4
H.R. 6163 112th 1
S. 3461 112th 1

From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.